Skip to Main Content

Paper Details

Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort.
BMC Med
18
2017
Cancer, ER, ER+, ER+ disease, ER-, ER- disease, OPG, Osteoprotegerin, RANK, RANK ligand, RANKL, TRAIL, Women, blood, breast cancer, estrogen, estrogen receptor, invasive breast cancer, osteoprotegerin, receptor activator of nuclear factor kappa-B, tumor necrosis factor-related apoptosis-inducing ligand, women
Author NameAffiliation
Ren??e T FortnerGerman Cancer Research Center (DKFZ)
Anne TjønnelandDanish Cancer Society Research Center
Kim OvervadAarhus University
Heiner BoeingGerman Institute of Human Nutrition Potsdam-Rehbruecke
Antonia TrichopoulouHellenic Health Foundation
Antonia TrichopoulouWHO Collaborating Center for Nutrition and Health, University of Athens Medical School
Domenico PalliCancer Research and Prevention Institute - ISPO
Hendrik B Bueno-de-MesquitaNational Institute for Public Health and the Environment (RIVM)
Hendrik B Bueno-de-MesquitaSchool of Public Health, Imperial College London
Hendrik B Bueno-de-MesquitaUniversity of Malaya
Petra H M PeetersJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht
Petra H M PeetersSchool of Public Health, Imperial College
Eiliv LundUniversity of Tromso, The Arctic University of Norway
María-José SánchezEscuela Andaluza de Salud Publica. Instituto de Investigacion Biosanitaria ibs. GRANADA. Hospitales Universitarios de Granada/Universidad de Granada
María-José SánchezCIBER de Epidemiologia y Salud Publica (CIBERESP)
Eva ArdanazCIBER de Epidemiologia y Salud Publica (CIBERESP)
Eva ArdanazNavarra Public Health Institute
Eva ArdanazNavarra Institute for Health Research
Timothy J KeyUniversity of Oxford
Kay-Tee KhawUniversity of Cambridge
Laure Dossus
Elio RiboliSchool of Public Health, Imperial College London
Rudolf KaaksGerman Cancer Research Center (DKFZ)
  • 1 - 23

Datasets

Release 1.2